Why the study?
Does meloxicam with heparin and aspirin reduce adverse outcomes in patients with acute coronary syndromes without ST-segment elevation?
Does meloxicam with heparin and aspirin reduce adverse outcomes in patients with acute coronary syndromes without ST-segment elevation?
In a pilot study, meloxicam added to heparin and aspirin was associated with reduced adverse outcomes in NSTE-ACS patients, though larger trials are needed.
Hypothesis-generating for meloxicam in NSTE-ACS; randomized trials needed before practice change.
Meloxicam with heparin and aspirin was associated with significant reductions in adverse outcomes in acute coronary syndrome patients without ST-segment elevation. Additional larger trials are required to confirm the findings of this pilot study.
No takes yet. Share an insight, caveat, or question.
Altman et al. (2002) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: